Audio is streamed directly from the publisher (mcdn.podbean.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Despite the successes of immunotherapies to date, about 75 to 80 percent of cancer patients don’t respond to current immunotherapy treatments. Faron Pharmaceuticals is hoping to help change that with its experimental therapy bexmarilimab, which is in development to treat myelodysplastic syndrome. Bexmarilimab targets CLEVER-1, a checkpoint inhibitor found on macrophages, a type of myeloid cell that plays an essential role in the immune system. We spoke to Juho Jalkanen, founder and CEO of Faron, about how the tumor microenvironment can suppress macrophages, how the company’s macrophage checkpoint inhibitor works, and the challenges a Finland-based company faces accessing the capital markets.